Maze Therapeutics (NASDAQ:MAZE) Trading Up 8.7% – Here’s Why

Maze Therapeutics, Inc. (NASDAQ:MAZE) shares shot up 8.7% on Friday . The company traded as high as $28.35 and last traded at $29.3630. 808,898 shares changed hands during mid-day trading, an increase of 17% from the average session volume of 692,634 shares. The stock had previously closed at $27.02.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on MAZE shares. JPMorgan Chase & Co. upped their price objective on Maze Therapeutics from $52.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, March 31st. Guggenheim lifted their target price on Maze Therapeutics from $46.00 to $58.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Wall Street Zen raised Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. HC Wainwright raised their price objective on Maze Therapeutics from $60.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, March 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Maze Therapeutics presently has an average rating of “Buy” and an average price target of $66.00.

Maze Therapeutics Price Performance

The company’s fifty day moving average is $25.64 and its two-hundred day moving average is $36.03. The company has a debt-to-equity ratio of 0.11, a quick ratio of 17.88 and a current ratio of 17.88. The firm has a market cap of $1.57 billion, a price-to-earnings ratio of -11.24 and a beta of 2.26.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The company had revenue of $20.00 million during the quarter. Equities research analysts forecast that Maze Therapeutics, Inc. will post -2.76 EPS for the current year.

Insider Activity

In related news, SVP Amy Bachrodt sold 2,500 shares of the business’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $29.44, for a total value of $73,600.00. Following the transaction, the senior vice president owned 12,965 shares in the company, valued at approximately $381,689.60. The trade was a 16.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 25,582 shares of the stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $26.02, for a total value of $665,643.64. Following the completion of the transaction, the chief executive officer directly owned 350,987 shares of the company’s stock, valued at $9,132,681.74. This represents a 6.79% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 102,360 shares of company stock worth $2,722,140. 5.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Maze Therapeutics

A number of institutional investors have recently made changes to their positions in MAZE. Royal Bank of Canada boosted its stake in shares of Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after buying an additional 363 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Maze Therapeutics in the fourth quarter worth $39,000. Caitong International Asset Management Co. Ltd acquired a new stake in Maze Therapeutics in the fourth quarter valued at $43,000. California State Teachers Retirement System boosted its stake in Maze Therapeutics by 138.0% during the 4th quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock valued at $55,000 after acquiring an additional 766 shares during the last quarter. Finally, Ameritas Investment Partners Inc. boosted its stake in Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after acquiring an additional 738 shares during the last quarter.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de?risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.